Cks1 proteasomal degradation is induced by inhibiting Hsp90-mediated chaperoning in cancer cells
- 28 December 2014
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 75 (2) , 411-420
Abstract
Cks1, a conformationally heterogenous 9 kDa protein, is markedly overexpressed in cancer cells and contributes to tumor development. Cks1 is an essential component of the SCF-Skp2 ubiquitin ligase complex that targets the Cdk inhibitors p27Kip1 and p21Cip1. Cks1 is known to interact with the Hsp90-Cdc37 chaperone machinery, although whether this facilitates its conformational maturation and stability is not known. To test whether abrogating the chaperone function of Hsp90 could destabilize Cks1, we examined the effects of treating different cancer cell lines with the benzoquinone ansamycin 17-allylamino geldanamycin (17-AAG), a compound that selectively binds Hsp90 and potently inhibits its ATP-dependent chaperone activity. The effect of Hsp90 inhibition using 17-AAG on Cks1 protein and associated cell cycle proteins including Skp2, p27Kip1, p21Cip1, and Cdk1 in cancer cells was determined by Western blotting. Ubiquitination analysis was carried out by transfecting cells with an HA-ubiquitin plasmid and specifically immunoprecipitating Cks1 to examine polyubiquitinated species. Flow cytometry was utilized to examine the effects of Hsp90 inhibition on cell cycle profiles. Here, we demonstrate for the first time that inhibition of Hsp90 utilizing 17-AAG destabilizes Cks1 in cancer cells by promoting its ubiquitination and proteasomal degradation. 17-AAG-induced Cks1 depletion was accompanied by concomitant decreases in Skp2 and Cdk1. 17-AAG treatment also induced G2/M accumulation in MCF-7 breast carcinoma cells, and G1 accumulation in the colon carcinoma lines HCT116 and SW620. We conclude that perturbing the Hsp90 pathway could provide a useful therapeutic strategy in tumors driven by Cks1 overexpression.Keywords
This publication has 35 references indexed in Scilit:
- Cyclin-dependent kinase subunit (Cks) 1 or Cks2 overexpression overrides the DNA damage response barrier triggered by activated oncoproteinsProceedings of the National Academy of Sciences, 2011
- Targeting the dynamic HSP90 complex in cancerNature Reviews Cancer, 2010
- CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myelomaHaematologica, 2010
- CKS Proteins Protect Mitochondrial Genome Integrity by Interacting with Mitochondrial Single-stranded DNA-binding ProteinMolecular & Cellular Proteomics, 2010
- Misfolded proteins partition between two distinct quality control compartmentsNature, 2008
- Cks1 Regulates cdk1 Expression: A Novel Role during Mitotic Entry in Breast Cancer CellsCancer Research, 2007
- Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesisThe EMBO Journal, 2007
- Expression of the Ubiquitin Ligase Subunit Cyclin Kinase Subunit 1 and its Relationship to S-Phase Kinase Protein 2 and p27 Kip1 in Prostate CancerJournal of Urology, 2006
- RNA Silencing of Cks1 Induced G2/M Arrest and Apoptosis in Human Lung Cancer CellsIUBMB Life, 2005
- Role of Conformational Heterogeneity in Domain Swapping and Adapter Function of the Cks ProteinsJournal of Biological Chemistry, 2005